Press Releases Year All202620252024202320222021202020192018201720162015 January 14, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical Read More January 5, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo ® Transcranial Magnetic Stimulation (TMS) machines nationwide. Program will unite common treatment protocols and clinical training with neurocare expertise in Read More Corporate Presentation Click here to view our corporate presentation or on the image below IP Portfolio View Our Pipeline Contact NRx Pharmaceuticals
Year All202620252024202320222021202020192018201720162015 January 14, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical Read More January 5, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo ® Transcranial Magnetic Stimulation (TMS) machines nationwide. Program will unite common treatment protocols and clinical training with neurocare expertise in Read More
January 14, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression. Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical Read More
January 5, 2026 NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo ® Transcranial Magnetic Stimulation (TMS) machines nationwide. Program will unite common treatment protocols and clinical training with neurocare expertise in Read More
